Study Design. Preclinical animal study. Objective. Determine the in vivo effects of platelet-derived growth factor BB (PDGF-BB) delivered in a thiol-modified hyaluronic acid (TMHA) hydrogel on intervertebral disk (IVD) degeneration. Summary of Background Data. IVD degeneration is a worldwide health concern and remains without an effective treatment.
I
ntervertebral disk (IVD) degeneration is established as a contributor to lower back pain. 1 The hallmarks of degenerative disc disease (DDD) are increased apoptosis and associated hypocellularity, 2,3 metabolic derangements such as decreased production of matrix proteins, 4 and the release of proteolytic enzymes. 5, 6 Although several growth factors/cytokines have demonstrated the potential to inhibit the effects of disc degenerative processes in vitro [7] [8] [9] [10] [11] and in vivo, [12] [13] [14] [15] [16] an ideal therapeutic strategy remains elusive. Platelet-derived growth factor BB (PDGF-BB) is a major component of platelet-rich plasma, and has been shown to be effective in a variety of orthopedic applications. 17, 18 Due to the variability in platelet-rich plasma quality, 19 a more reproducible constituent such as PDGF-BB has promised for orthobiologic applications. In vitro studies have shown that while PDGF, basic fibroblast growth factor (bFGF), and insulin-like growth factor-I (IGF-I) were all capable of inducing cellular proliferation of nucleus IVD cells, PDGF-BB was the most potent at inducing DNA synthesis in quiescent cells. 9, 10 PDGF-BB has previously been implicated in chemoattraction 20, 21 and angiogenesis by modulating vascular endothelial growth factor expression. 22 , 23 We have shown that PDGF-BB inhibits apoptosis in both monolayer and 3-D pellet culture of IVD cells. 7, 9, 10 From the UConn Health Center, Department of Orthopaedic Surgery, Farmington, CT.
The purpose of this study was to determine the effects of rhPDGF-BB on injured rabbit IVDs. Our hypotheses were that treatment of injured IVDs during midstage disc degeneration would inhibit degeneration, and these effects could be enhanced through gradual release from a hydrogel. To verify our hypothesis, we evaluated injured and subsequently treated IVDs, to determine the loss in disc height, magnetic resonance imaging (MRI) indices, gross histomorphometric appearance, production of degenerative matrix, initiation of cell apoptosis, and biomechanical properties of the IVDs.
MATERIALS AND METHODS

Growth Factor and Hydrogel Preparation
Recombinant human PDGF-BB (Pepro Tech Inc., Rocky Hill, NJ) was reconstituted in 0.1% BSA and diluted with sterile water to achieve a concentration of 1 ng/mL. For the hydrogel experiments, this concentration of rhPDGF-BB was also supplemented into a Hystem-C thiol-modified hyaluronic acid (TMHA) hydrogel kit with PEGSSDA (BioTime Inc., Alameda, CA) prior to cross-linking, to prolong growth factor release. Prolonged release of PDGF-BB has been previously characterized for this hydrogel [24] [25] [26] [27] in vitro. We have demonstrated successful encapsulation and functional stability of IVD cells in this hydrogel. 28 
Rabbit Annular Puncture Model
After institutional animal care committee (IACUC) approval, IVD degeneration was induced in 25 mature male New Zealand white rabbits (3-3.5 kg weight) by puncture of the annulus fibrosus of four lumbar IVDs (L3-4 to L6-7), as we have previously desribed. [14] [15] [16] Rabbits were randomly assigned to one of four groups: (I) sterile saline control, (II) 1 ng/mL recombinant human PDGF-BB (rhPDGF-BB), (III) TMHA hydrogel, or (IV) 1 ng/mL PDGF in TMHA hydrogel (n ¼ 12 discs per group at each time point). Group size was determined based on the variation we expected in mechanical testing values from a similar study. 16 
Induction of IVD Degeneration
After appropriate surgical preparation, an anterolateral retroperitoneal approach to the spine was performed, as previously described. 15, 16, 29 The IVD was punctured to a depth of 5 mm using an 18G needle/syringe with a pretrimmed cap to control for depth and rotated 3608 with suction. The puncture procedure repeated at three additional levels. Rabbits were sutured and recovered according to IACUC guidelines.
Revision Surgery/Experimental Treatment
Four weeks after injury, the rabbits were prepared for a contralateral retroperitoneal approach to the spine. Injured IVDs were injected with a 20-mL disc treatment solution according to group assignment, as described above, using a Model 1710 LT Hamilton Syringe (Hamilton Company, Reno, NV). Rabbits were sutured and recovered according to IACUC guidelines.
Imaging and Tissue Harvest
At 4 and 8 weeks after revision surgery rabbits were sacrificed and sagittal MRIs were obtained (L2-3 to L6-7) using a Siemens MAGNETOM Avanto 1.5-T magnet and standard human brain coil, to obtain T2 images 30 with a fast spin echo sequence (repetition time ¼ 3500 ms, echo time [TE] ¼ 100 ms, 144 Â 256 voxel matrix, slice thickness ¼ 3 mm, gap ¼ 1.1 mm). Midsagittal T2 images were used for image processing. MRI images were analyzed as DICOM files to determine the area (pixels 2 ) and signal intensity (0-255) of IVDs, using ImageJ (NIH freeware). MRI indices were calculated by multiplying the NP area by the intensity as previously described. 28 After MRIs, the discs were processed for histology (n ¼ 6) and mechanical testing (n ¼ 6).
Histologic Processing and Scoring
After MRI, the entire lumbar spine of rabbits was isolated. Samples used for histological processing were separated from those used for mechanical testing with an electric bone saw through the vertebral body. Lumbar spines were fixed in 4% formalin for 3 weeks followed by EDTA decalcification. Samples were dehydrated, fixed in xylene, and embedded in paraffin wax, as previously described. 15, 16 Sections were captured at a thickness of 7 mm on charged slides and later stained for histologic evaluation. The Thompson scale (4-12 points) was used 14, 15 to characterize the extent of disc degeneration with a score of 12 points being the most severe degeneration. Slides were also processed to determine the glycosaminoglycan (GAG) content within each section using Alcian Blue solution (Poly Scientific, Bay Shore, NY) and Nuclear Fast-Red (Poly Scientific).
Immunohistochemistry and Nerve Stain
Serial sections from paraffin blocks that had been previously processed for histology were used for immunohistochemistry (IHC). To evaluate the extent of collagen 3a1 production in the NP, where it is found in degenerating discs, an anticollagen III (Col-29) monoclonal antibody (ABCAM, Cambridge, MA, 1:20 dilution) was used followed by an antimouse secondary antibody #PI-2000 (Vector Labs, Burlingame, CA). Staining was revealed using an AEC (red) substrate kit (Thermo Fischer Scientific, Waltham, MA) 7 ; IHC was also performed to evaluate cell apoptosis using a polyclonal primary antibody (1:300 dilution of antibody #9661; Cell Signaling Technology, Beverly, MA) that specifically recognizes the large fragment (17/19 kDa) of activated, but not full length, caspase-3 (Asp175), and SignalStain boost detection reagent (secondary antibody/ amplification; Cell Signaling Technology), as previously described. 7, 31, 32 Slides were revealed using a SignalStain DAB working solution (Cell Signaling Technology). All slides were counterstained with hematoxylin (Poly Scientific) to visualize cell nuclei and images were captured at 4Â, 10Â, and 20Â under a light microscope. The number of cleaved caspase-3 positive cells was measured from digital images using Image Pro Plus Software (Media Cybernetics, Inc., Silver Springs, MD) and normalized to the total area of the IVD (mm 2 ). To evaluate the extent of blood vessel infiltration of the disc, a CD-31 antibody staining was used.
To evaluate the extent of PDGF receptor protein expression in the disc, an anti-PDGF receptor a antibody (ABCAM, 1:20 dilution) was used followed by an antimouse secondary antibody #PI-2000 (dilution 1:100, Vector Labs). Staining was revealed using an AEC (red) substrate kit (Thermo Fischer Scientific, Waltham, MA). All slides were cover-slipped using an aqueous mounting media. The cell nuclei were visualized and images were captured at 10Â, 20Â, and 40Â using light microscopy.
To evaluate the extent of blood vessel infiltration of the disc a CD-31 antibody staining was used. A monoclonal mouse CD31 endothelial cell (Dako North America, Carpinteria, CA, 1:50 dilution) primary antibody was used followed by an antimouse secondary antibody antimouse secondary antibody #PI-2000 (1:100 dilution, Vector Labs). Slides were revealed using a SignalStain DAB working solution (Cell Signaling Technology). All slides were counterstained with hematoxylin (Poly Scientific) and coverslipped using a permanent mounting media. The cell nuclei were visualized and images were captured at 10Â, 20Â, and 40Â using ZEN Digital Imaging for light microscopy.
To evaluate the extent of innervation of the disc, a modified Bielschowsky silver stain (American MasterTech # KTBIE) was used. The slides were rinsed twice in dH 2 O and placed in a preheated silver nitrate solution for 15 minutes at 408C. Slides were thoroughly rinsed with three changes of dH 2 O and placed in a preheated ammoniacal silver solution for 10 minutes at 408C. Slides were developed using the developer solution, agitated for 3 to 30 seconds, and placed in ammonia water to stop the developing process. Slides were rinsed thoroughly in three changes of dH 2 O, followed by placement in 5% sodium thiosulfate solution for 2 minutes. The nerve staining was visualized and images were captured at 10Â, 20Â, and 40Â using ZEN Digital Imaging for light microscopy.
Biomechanics
Functional spinal units (FSUs), consisting of the IVD and 15 mm of adjacent vertebral bodies with the posterior elements removed through the pedicles, were cleaned of exogenous soft tissue. Individual FSUs were hydrated in saline for 2 hours prior to testing, to allow the NP to swell. Figure 1 . MRI demonstrated evidence of more hydrated IVDs (A,B) with larger disc area at 8 weeks postinjection, which was significantly higher (P < 0.05) for the PDGF-BB-treated groups, compared to the HA gel controls (C). This resulted in significantly higher (P < 0.05) MRI indices for PDGF-BB-treated IVDs, compared to HA gel controls (D) at 8 weeks.
Samples were placed in anatomical position on a stainless steel porous puck (100 mm stainless steel, Mott Corporation, Farmington, CT) in a saline bath and subjected to a 5-N force (unloaded condition) to maintain sample surface contact throughout testing (Supplementary Figure 1 , http:// links.lww.com/BRS/B70).
Samples were preconditioned 15, 16 through 10 cycles of uniaxial compressive loading, applied in cycles of 2% to 5%, 2% to 7.5% strain (1 Hz frequency, 0.01 mm/s) with 3-minute relaxation intervals between each set of cycles. After preconditioning, samples were subjected to 10 cycles of loading (2%-10% strain, 1-Hz frequency, 0.01 mm/s) to mimic gait. After unloading, samples were ramped to a constant force of 400 N (half of the yield strength of a healthy disc) and monitored during stress relaxation for 10 minutes to simulate vigorous exercise. Ramp-phase stiffness (k) was calculated for each FSU and the ability to achieve the creep load relaxation was evaluated. After stress relaxation and unloading, samples were loaded until failure in uniaxial compression, with a 15% to 20% reduction in force set as the failure criterion. All samples were tested in all modalities and subsequently evaluated to determine if they failed during cyclic or stress relaxation conditions, prior to the load to failure testing.
Statistical Analysis
Statistical analyses were conducted using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA). For nonparametric data, a Mann-Whitney U test was performed to determine if nonhistologic scores were significantly different (P 0.05) between groups. For parametric data, an analysis of variance (ANOVA) was performed to determine differences between three or more groups, followed by Bonferroni post hoc tests and to determine statistical differences. Statistical significance was established at P 0.05.
RESULTS
MRI
Analysis of sagittal T2 MRI images found that there are no significant differences between groups after 4 weeks posttreatment. At 8 weeks post-treatment, PDGF-treated discs with or without the TMHA hydrogel had significantly greater area and higher MRI indices (P < 0.05) compared to the TMHA-only or the saline control groups Figure 1 . In some cases the level above the punctured discs (noninjured) exhibited signs of degeneration, possibly due to the loss of integrity of adjacent levels. Noninjured discs with obvious degeneration on MRI were omitted from downstream analyses.
Histology
Gross morphometric staining for H&E demonstrated significant visible degeneration for both control groups (saline and TMHA) at 8 weeks post-treatment, compared to experimental groups (PDGF and PDGF TMHA) (Figures 2 and 3) . Thompson scoring of the FSUs (Table 1) confirmed this finding for both controls versus PDGF groups (P < 0.001) and also found evidence of significantly more degeneration in PDGF versus PDGF TMHA (P < 0.05). Alcian blue staining verified the presence of proteoglycans matrix in the cartilage endplate, which was more intense for PDGFtreated rabbits, compared to controls (Figure 4 ).
IHC
IHC staining for collagen III qualitatively exhibited more matrix staining in the NP of IVDs from both control groups compared to PDGF-treated groups at 4 and 8 weeks posttreatment ( Figure 5 ). IHC staining for cleaved caspase-3 found significantly more (P < 0.001) caspase-3 positive cells per mm 2 in both saline and TMHA gel controls, compared to untreated, and PDGF-and PDGF-TMHA-treated IVDs at 4 weeks post-treatment, specifically staining the nuclei of cells surrounding areas of early to moderate disc degeneration, but not around areas of severe degeneration (Figures 6  and 7 ). PDGF-treated discs without TMHA demonstrated low levels of apoptosis at 4 weeks post-treatment and moderate degeneration in several discs at 8 weeks after treatment. PDGF-TMHA-treated discs maintained the morphology of the NP and cellular content with the least evidence of apoptosis or degeneration of any experimental group.
At all-time points, there was evidence of comparable PDGF receptor immunohistochemical staining in both the AF and NP of discs, regardless of treatment regimen 
Biomechanics
Cyclic loading analysis at 4 and 8 weeks post-treatment found that several discs in both control groups failed during the 10% strain condition, exhibiting a ductile response to applied load, prior to failure (Table 2 ). In contrast, fewer discs failed during cyclic loading for the PDGF and PDGF TMHA groups. Additionally, fewer PDGF-TMHA-treated discs exhibited signs of degeneration ( Figure 11 ) when subjected to stress relaxation from a 400-N load, compared to other groups at both time points (Table 2 ). When FSUs were tested in compressive load to failure, PDGF-treated discs exhibited higher compressive yield strength than controls, which was statistically significant for PDGF (P < 0.05) and PDGF-TMHA (P < 0.001) versus controls at 8 weeks post-treatment ( Figure 12 ).
DISCUSSION
We evaluated the effects of PDGF-BB on IVD degeneration when administered 4 weeks after injury. Previous studies and our recent work have demonstrated the proliferative and antiapoptotic effects of PDGF-BB on human IVD cells in monolayer and 3-D culture. [7] [8] [9] [10] While these in vitro studies are highly informative, they cannot recapitulate the native disc microenvironment and simulate cell densities that are present in vivo. This is the first study designed to evaluate the effects of PDGF-BB on the IVD in a preclinical model. We chose to treat IVDs with midstage degeneration (Pfirrmann grades II or III), which were verified radiographically prior to the revision surgery and previously reported for this model, 15, 16, 29 where tissue architecture is still adequately preserved and the growth factor stimulation has the potential to inhibit progression and possibly reversed disc degeneration. Although PDGF is a potent inducer of vascular endothelial growth factor, using stains specific for nerve and blood vessel infiltration, we did not detect any changes after PDGF treatment. We found that rhPDGF-BB treatment of IVDs in the midstages of degeneration inhibited disc cell apoptosis and Col3 matrix deposition, halting the progression of degeneration, and preserving the biomechanical properties of the IVD.
Similar to findings from preclinical IVD growth factor studies, 14 -16 PDGF-BB treatment was able to preserve the IVD architecture and limit the disruption to the NP-AF boundary. This was evidenced with growth factors such as bone morphogenic protein 7 (osteogenic protein 1:OP-1), 14, 15 growth differentiation factor 5 (GDF-5), 12 and adeno-associated viral vectors for bone morphogenic protein 2 (BMP-2), GDF-5, and tissue inhibitor of metalloproteinase 1 (TIMP-1), 13, 16 where MRI indices, disc area, and IVD architecture were preserved up to 12 weeks after growth factor treatment. This was also evident in our study following where T2 MRI signal intensity was only slightly reduced in PDGF-and PDGF-TMHA-treated discs, compared to uninjured IVDs. In the saline control and TMHA-only group, there was a significant decrease in disc signal intensity compared to healthy NP tissue. Additionally, there were minimal histological differences between the uninjured and PDGF-TMHA-treated groups, while PDGF-treated IVDs demonstrated a loss of distinction between the NP and AF boundary. The saline and TMHA-only control IVDs were characterized by significantly higher histomorphometric degenerative scores, indicative of severe degeneration at 8 weeks. This provides evidence that local PDGF-BB treatment during midstage degeneration preserves IVD architecture.
The progression of disc degeneration was decelerated with PDGF in TMHA, with no increase in degenerative scores from 4 to 8 weeks post-treatment, similar to what was seen with TGF-b3 in an organ culture lumbar discectomy model. 33 In contrast, saline-and TMHA-treated IVDs demonstrated significant degeneration of the NP and associated hypocellularity, tearing of the AF, and deposition of Col3 matrix within the NP. Col3 is not normally seen in NP tissue and is commonly seen in tissues that express type 1 collagen, indicative of a transition toward fibrotic tissue. It has been implicated in degenerative disease processes and has been previously shown to be increased in the AF of degenerated discs. 34 We detected abundant Col3 in the AF and NP of saline and TMHA-treated discs at 4 and 8 weeks posttreatment. This could potentially be due to the loss of demarcation between the NP and AF during the progression of IVD degeneration. While many other studies have characterized Col2a1 in the disc after degeneration to determine the degenerated versus healthy disc phenotype, 34, 35 ours is the only study to our knowledge to evaluate Col3 and its association with DDD. 34 Taken together, these findings provide evidence that treatment of PDGF after moderate degeneration maintains disc architecture and hydration and that this effect is potentiated when PDGF is delivered in a TMHA hydrogel.
In addition to preservation of tissue architecture and hydration, IVDs treated with PDGF-BB demonstrated biomechanical integrity comparable to the uninjured IVD, similar to what has been reported for BMP-2, OP-1, and TIMP-1 at 12 weeks after treatment in the same rabbit injury model. [14] [15] [16] Biomechanically, both PDGF and PDGF-TMHA demonstrated a significantly higher compressive load to failure than saline and TMHA-only controls. Other studies have also reported improved biomechanical properties of BMP-2-and OP-1-treated IVDs, 15, 16 though these studies mainly characterized the behavior of the IVD when subjected to a cyclic load or a maintained load. Our results found that fewer IVDs treated with PDGF and PDGF-HA failed in cyclic loading. We also found less evidence of disc deficiencies, particularly with ramp phase stiffness and stress relaxation in PDGF-TMHA-treated IVDs. Although treatment with PDGF alone was superior to controls, there exists evidence of degeneration at 8 weeks post-treatment, emphasizing the importance of the TMHA gel for growth factor storage and release. These results suggest that prolonged PDGF-BB treatment completely inhibits biomechanical degeneration of the IVD (Figure 6 ), which is pronounced at 8 weeks post-treatment in the control groups. Similar to the in vitro studies, 7, 8 PDGF-BB treatment significantly inhibited cell apoptosis in vivo. Although the initiation of apoptosis decreased in untreated pellets by day 14 after IVD pellet culture 7 further initiation of apoptosis continued in vivo at 8 weeks post-treatment. These differences may be due to the influence of other caspases in pellet culture at day 14, as well as the complexity of the in vivo model. Previous literature has suggested that PDGF promotes cell survival through PI3 kinase-Akt signaling pathway 36, 37 and that phosphorylation of NF-kB is primarily responsible for inhibition of apoptosis in vitro.
36 PDGF-BB has also been shown to suppress interleukin 1 b-induced cartilage degradation through downregulation of NF-kB signaling. 37 This supports our initial hypothesis and findings that PDGF-BB is capable of inhibiting apoptosis in vivo, similar to what we and others have seen in vitro. Future studies will evaluate the precise mechanism behind PDGF signaling in this model, including this growth factor's antiapoptotic effects and potential mitogenic effects.
This study presents many interesting findings; however, it has several limitations. Although PDGF certainly appears to be a promising anabolic agent, we have not quantitatively characterized its metabolism nor its in vivo release from the TMHA gel. In addition, we have not determined the exact underlying biochemical pathways by which it produces these effects. Further studies could investigate which cell receptors are activated or inhibited upon PDGF treatment in order to help better understand how PDGF modulates the effects described here. Despite these limitations, we are encouraged by the results of this study and feel that additional preclinical studies will provide valuable information necessary for future translational approaches.
Key Points
Growth factors therapy has potential as a minimally invasive treatment for DDD. PDGF-BB has been previously shown to inhibit IVD cell apoptosis and promote proliferation. When injected into an injured rabbit IVD, PDGF-BB decreased the severity of degeneration based on MRI, histologic, and biomechanical evaluation. Delivery of PDGF-BB in a thiol-modified hyaluronan hydrogel maintained IVD structure and biomechanical function while inhibiting apoptosis and Col3a matrix deposition. No increase vascular or nerve ingrowth was seen with PDGF treatment.
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